Direct weight-matched ethnic comparison
The primary 200 mg SC comparison enrolled 12 Japanese and 13 weight-matched White participants, directly addressing the stated ethnic-bridging objective.
↳ Methods, Study Design; Results, Study Participants
Abstract
Garadacimab, an activated factor XII (FXIIa) inhibitor monoclonal antibody, is being evaluated for the long-term prophylaxis of hereditary angioedema. Here, we report the results from a two-part, phase 1, open-label, single ascending dose study assessing the pharmacokinetics (PK), pharmacodynamics, safety, and tolerability after subcutaneous (SC) and intravenous (IV) administration of garadacimab in healthy Japanese and White participants. Part 1 assessed garadacimab PK after SC administration of a 200 mg dose in weight-matched White and Japanese participants, and 600 mg dose in Japanese participants. Part 2 assessed 3 and 10 mg/kg IV doses in Japanese participants. Follow-up for safety was over 84 days post-dose. Overall, 37 participants received garadacimab dosing and 36 completed the study, with one participant lost to follow-up. Following SC administration, time to maximum plasma concentration (tmax) occurred at 7 days post-dose, and garadacimab exposure, based on maximum plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC), increased less than 3-fold when tripling the dose. PK was comparable between Japanese and White participants, with geometric mean ratios for Cmax and AUC close to 100%. Following IV administration, tmax occurred at the end of infusion, and garadacimab exposure increased in a dose-proportional manner. Inhibition of FXIIa-mediated kallikrein activity versus baseline was observed in all participants receiving the SC and IV doses. No anti-drug antibodies against garadacimab were reported. Consistent with pivotal phase 3 (VANGUARD) outcomes, no safety concerns and no difference in the safety profile of garadacimab were observed between healthy Japanese and White participants.
Key Claims
Primary findingTentative
This phase 1 study showed comparable PK, PD, and safety/tolerability profiles in Japanese and weight‐matched White participants following administration of garadacimab 200 mg SC.
Fragile — the claim's weakest requirement is that the effect exists at all. Based on how the study was designed and conducted, not on statistics extracted from the paper. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
small healthy-volunteer groups and broad PK intervals limit the combined comparability claim
Conclusions
SecondarySupported
Inhibition of FXIIa-mediated kallikrein activity versus baseline was observed in all participants receiving the SC and IV doses.
consistent descriptive profiles, although PD assessment relied on visual inspection rather than formal testing
Abstract; Results, Pharmacodynamics
SecondaryWell-supported
No anti-drug antibodies against garadacimab were reported.
direct immunogenicity observation across the reported 84-day follow-up period
Abstract; Results, Safety and Tolerability
SecondaryTentative
Consistent with pivotal phase 3 (VANGUARD) outcomes, no safety concerns and no difference in the safety profile of garadacimab were observed between healthy Japanese and White participants.
small open-label cohorts were not designed to establish comparative safety equivalence
Abstract; Discussion
Derived from the full evaluation — not a separate score.
Strengths · Limitations
Strengths
Transparent anomalous-participant analysis
The unusually high early concentrations in one Japanese participant were disclosed, investigated, and examined through exclusion analyses; the principal PK and PD interpretations remained unchanged.
↳ Results, Garadacimab Concentrations, Pharmacokinetic Parameters, and Pharmacodynamics
Concrete regulatory-development pathway
The Discussion ties the study to limited Asian representation in phase 2 and states that the resulting evidence enabled Japanese patient inclusion in the global phase 3 program.
↳ Discussion, first and final paragraphs
Limitations
Comparability wording exceeds statistical precision
The Cmax GMR was 1.17 with a 90% CI of 0.82–1.67, while the abstract describes both GMRs as close to 100% and the conclusions extend the finding to no dose adjustment.
↳ Abstract; Results, Comparison of Japanese and White Participants; Conclusions
Exploratory cohorts provide limited precision
The 600 mg SC and both IV cohorts each included four treated participants, limiting confidence in higher-dose, route-specific, and comparative safety conclusions.
↳ Methods, Study Design and Statistical Analysis, Sample Size
IV dose-response description is contradictory
The Results report dose-proportional increases in IV Cmax and AUC, but the Discussion states that mean Cmax and AUC did not change as dose increased.
↳ Results, Pharmacokinetic Parameters; Discussion, paragraph discussing IV administration
Nabu Commentary
The primary design directly addresses the ethnic-bridging objective through a weight-matched Japanese–White comparison and reports GMRs with 90% confidence intervals. Transparent investigation and sensitivity analysis of the anomalous Japanese participant strengthen the PK assessment, although the n=4 exploratory cohorts and visually assessed PD profiles leave meaningful uncertainty. The principal score constraint is interpretive: broad intervals and descriptive safety data are translated into categorical comparability and no-dose-adjustment language. The paper nevertheless has a concrete development pathway because the Discussion states that these data enabled Japanese inclusion in the global phase 3 program.
Check another paper
Author Note / Field Feedback
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Dimension breakdown
Study Quality
Sound3.3
Confidence highContribution
3.3
The study supplies a direct, weight-matched Japanese–White comparison at the clinically developed 200 mg SC dose and fills a documented ethnic-representation gap. The advance is decision-relevant but narrow and specific to one development program.
Introduction, study objectives; Discussion, first paragraph
“due to the limited number of Asian participants recruited in the phase 2 study (6%, n = 2)”
Methodological Rigour
3.3
Body-weight matching, prolonged sampling, noncompartmental PK analysis, reported confidence intervals, and outlier sensitivity analyses fit the primary bridging objective. Precision is constrained by n=4 exploratory cohorts, and PD effects were assessed by visual inspection rather than formal comparison.
Methods, Study Design and Statistical Analysis; Results, Pharmacokinetics and Pharmacodynamics
“as indicated by visual inspection of the PK and PD profiles”
Reporting
3.3
The article is logically structured and reports the key GMRs with 90% confidence intervals. However, “comparable” profiles and “no need for dose adjustments” communicate greater certainty than the broad intervals and descriptive safety evidence support.
Abstract; Results, Comparison of Japanese and White Participants; Conclusions
“with no need for dose adjustments”
Positioning
3.3
The Discussion connects the study to the first-in-human, phase 2, pivotal phase 3, and extension programs and identifies the regulatory rationale. It does not fully carry the small-sample and interval-width limitations into the categorical dose-adjustment conclusion.
Discussion; Conclusions
“enabled the inclusion of Japanese patients with HAE into the global phase 3 program”
Lower confidence on Methodological Rigour, Positioning — domain match limited.
Reliability
Caveats4 of 4 checks
Internal CoherenceNoted
A localized contradiction appears between the IV dose-response findings and their description in the Discussion. The participant flow, primary Japanese–White estimates, and handling of the anomalous participant otherwise reconcile internally.
Research ConductNoted
Ethics approval, consent, registration, funding, conflicts, and a process-based data-sharing pathway are declared. Extensive sponsor employment and shareholding across the author group remain relevant context for interpreting the uniformly favorable safety framing.
Flags: 4 declared / 5 total
Reference IntegrityClean
30 of 30 checkable references verified
32 references in manuscript 2 are books, websites or datasets — counted, but not index-checkable
Post-Publication RecordClean
No retraction notice found in Retraction Watch.
Last checked: 18 Sep 2026
Sources: Retraction Watch ✓
Readiness
Where this paper’s evidence sits on the path from initial observation to real-world use.
Validated
Readiness extends beyond a proposed pathway because the study informed Japanese inclusion in phase 3. It remains controlled phase 1 evidence in healthy volunteers and does not itself demonstrate long-term use in Japanese HAE patients.
Methods, Study Design; Discussion, final paragraph
“healthy Japanese and White participants”
AI-generated, human-governed. Something look off? Contact us to request a review.